Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Cencora, Inc. (COR) Halal?

PASS

Cencora, Inc. · NYSE: COR · Healthcare

The short answer

Yes - Cencora, Inc. (COR) passes this Shariah stock screen on all three gates. Its FY2025 10-K describes one of the largest global pharmaceutical sourcing and distribution businesses (U.S. Healthcare Solutions $291.0B plus International Healthcare Solutions $30.4B, incl. Alliance Healthcare) with no reportable segments involving alcohol, tobacco, gambling, or conventional lending. Interest-bearing debt of $7,660.8M (short-term debt $117,785K + long-term debt $7,542,988K) is about 12.75% of its ~$60.10B market cap ($309.78, October 2, 2026; 193,993,444 shares outstanding), below the ~33% ceiling. Interest income of $128,205K - separately disclosed in the 10-K's MD&A - is about 0.04% of total revenue ($321,332,819K), below the 5% ceiling. Musaffa classifies COR halal as of October 2026; Zoya covers COR (its page's rating label renders ambiguously and is not quoted); no ShariaPortfolio rating was found - honestly reported as absent, not invented.

Gate 1 — Business activity: PASS

Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation (renamed August 2023), is described in its FY2025 10-K (fiscal year ended September 30, 2025) as one of the largest global pharmaceutical sourcing and distribution services companies, based in Conshohocken, Pennsylvania. It reported two reportable segments for FY2025: U.S. Healthcare Solutions ($290,982,023K revenue - Human Health brand-name, specialty, plasma, injectable and vaccine distribution of $285,287,506K plus Animal Health of $5,694,517K) and International Healthcare Solutions ($30,366,323K - Alliance Healthcare $24,394,833K plus Other Healthcare Solutions $5,971,490K). Customers include acute care hospitals and health systems, retail and mail-order pharmacies, medical clinics, physicians specializing in oncology and retina, dialysis clinics, and veterinary customers. Haram flags (factual, from the filing): none - the 10-K discloses no alcohol, tobacco, gambling, or conventional lending segments; the Animal Health business sells pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients to companion-animal and production-animal markets, all permissible activities. Interest income is incidental to cash balances (0.04% of revenue), not a lending business. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Cencora's FY2025 10-K (fiscal year ended September 30, 2025), interest-bearing debt was $7,660.8M - short-term debt $117,785K plus long-term debt $7,542,988K (the balance sheet presents these two debt lines; no separate current-portion-of-long-term-debt line is shown). Against a market cap of about $60.10B ($309.78 close on October 2, 2026; 193,993,444 shares outstanding per the 10-K cover), debt / market cap is about 12.75%, below the ~33% ceiling. Cash and cash equivalents of $4,356.1M are about 7.25% of market cap. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Cencora's FY2025 10-K separately discloses interest income of $128,205K in its MD&A interest breakdown (interest expense $419,753K, interest income $128,205K, interest expense, net $291,548K) against total revenue of $321,332,819K - about 0.04% of revenue, far below the 5% non-compliant income ceiling. Gate 3 passes. Facts only.

Key figures used

Frequently asked questions

What does Cencora do?

Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation (renamed August 2023), is one of the largest global pharmaceutical sourcing and distribution services companies, based in Conshohocken, Pennsylvania. Per its FY2025 10-K (fiscal year ended September 30, 2025), it operates in two reportable segments: U.S. Healthcare Solutions ($291.0B revenue - Human Health pharma distribution $285.3B plus Animal Health $5.7B) and International Healthcare Solutions ($30.4B - Alliance Healthcare $24.4B plus Other Healthcare Solutions $6.0B). Its customers include hospitals and health systems, retail and mail-order pharmacies, medical clinics, physicians (especially oncology and retina), and veterinary practices.

Why does Cencora pass this Shariah stock screen?

Cencora passes this screen's business-activity gate. Its FY2025 10-K describes pharmaceutical sourcing and distribution for human and animal health, with no reportable segments involving alcohol, tobacco, gambling, or conventional lending. Its animal health business sells pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients to companion-animal and production-animal markets - all permissible activities under the screen. Interest income is incidental (about 0.04% of revenue, from cash balances), not a lending business. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

What is Cencora's interest-bearing debt ratio?

Per Cencora's FY2025 10-K balance sheet (September 30, 2025), interest-bearing debt was $7,660.8M - short-term debt $117,785K plus long-term debt $7,542,988K (the balance sheet presents these two debt lines). Against a market cap of about $60.10B ($309.78 close on October 2, 2026; 193,993,444 shares outstanding per the 10-K cover), debt / market cap is about 12.75% - below the ~33% ceiling. Cash and cash equivalents of $4,356.1M are about 7.25% of market cap.

What is Cencora's non-compliant income ratio?

Cencora's FY2025 10-K discloses interest income of $128,205K in its MD&A interest-expense breakdown (interest expense $419,753K less interest income $128,205K = interest expense, net $291,548K). Against total revenue of $321,332,819K, that is about 0.04% of revenue - far below the 5% non-compliant income ceiling. Note: the Q3 FY2026 10-Q (quarter ended June 30, 2026) had not yet been retrieved from a readable primary source, so these figures use the audited FY2025 10-K, consistent with prior screens.

Do Zoya, Musaffa, or ShariaPortfolio cover Cencora?

Musaffa covers COR and classifies it halal as of October 2026 (musaffa.com/stock/COR/). Zoya also has a COR stock page (zoya.finance/stocks/cor) citing interest income of about 0.04% of revenue, but the page's compliance-status text renders with conflicting template phrasing, so no clean Zoya rating and date can be quoted here - honestly reported, not invented. No ShariaPortfolio screening page or rating for COR was found - reported as absent, not invented. This page applies the screen directly from Cencora's own filings and reports these positions honestly.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).